Quantifying the benefits of genome-driven oncology Journal Article

   


Authors: Schram, A. M.; Hyman, D. M.
Article Title: Quantifying the benefits of genome-driven oncology
Abstract: The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. © 2017 AACR.
Keywords: oncology; cancer therapy; clinical study; screening; genome; human; male; female; excitement
Journal Title: Cancer Discovery
Volume: 7
Issue: 6
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2017-06-01
Start Page: 552
End Page: 554
Language: English
DOI: 10.1158/2159-8290.cd-17-0380
PROVIDER: scopus
PUBMED: 28576841
PMCID: PMC5500977
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020385299&doi=10.1158%2f2159-8290.CD-17-0380&partnerID=40&md5=2f942247d3fc8eb2cf958bbce5b49ebf
Notes: Article -- Export Date: 3 July 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Hyman
    354 Hyman
  2. Alison Michele Schram
    122 Schram
Related MSK Work